BACKGROUND: Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. METHODS: Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. RESULTS: A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P < 0.001). In a multivariate adjusted analysis, absence of an antibody response was independently associated with KT (odds ratio 20.56, P = 0.001) and with BNT162b2 vaccine (odds ratio 6.03, P = 0.023). CONCLUSION: The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.
BACKGROUND: Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. METHODS: Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. RESULTS: A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P < 0.001). In a multivariate adjusted analysis, absence of an antibody response was independently associated with KT (odds ratio 20.56, P = 0.001) and with BNT162b2 vaccine (odds ratio 6.03, P = 0.023). CONCLUSION: The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.
Authors: Borja Quiroga; María José Soler; Alberto Ortiz; Esther Orero; Sandra Tejedor; Carlos Jesús Jarava Mantecón; Virginia Olinda Gómez Pérez; Antonio José Marín Franco; Christian Alfaro Sánchez; Marta Puerta Carretero; María Teresa Jaldo Rodríguez; Manuel Antonio Carnerero Di Riso; Shaira Martínez; Carmen Calderón González; Michal Cervienka; Nicolás Macías Carmona; David Arroyo; Katia M Pérez Del Valle; Gabriel de Arriba; Auxiliadora Mazuecos; Juan Manuel Cazorla; Mónica Pereira; Emilio González Parra; María Gabriela Sánchez Márquez; Carolina Lancho Novillo; Carmen Toyos Ruiz; María Cinta Aguilar Cervera; Patricia Muñoz Ramos; Ana Sánchez Horrillo; Isabel Jimeno Martín; Néstor Toapanta; Secundino Cigarrán Guldris; Montserrat Folgueiras López; Rosalía Valero San Cecilio; Blanca Villacorta Linaza; Ignacio Minguela Pesquera; Raquel Santana Estupiñán; Rocío Zamora; Sagrario Soriano; Eduardo Muñoz de Bustillo; María Soledad Pizarro Sánchez; Ana Isabel Martínez Puerto; Alejandra Yugueros; Laura Muñiz Pacios; Alba Leyva; José Rojas; Ron T Gansevoort; Patricia de Sequera Journal: Clin J Am Soc Nephrol Date: 2022-05-12 Impact factor: 10.614
Authors: Nayara Panizo; Eliseo Albert; Elena Giménez-Civera; Maria Jesús Puchades; Luis D'Marco; Lorena Gandía-Salmerón; Estela Giménez; Ignacio Torre; Asunción Sancho; Eva Gavela; Miguel Gonzalez-Rico; Marco Montomoli; Carmen Maria Perez-Baylach; Begoña Bonilla; Camila Solano; Mª Fernanda Alvarado; Isidro Torregrosa; María Jesús Alcaraz; José Luis Górriz; David Navarro Journal: Clin Kidney J Date: 2022-04-09
Authors: Lukas Buchwinkler; Claire Anne Solagna; Janosch Messner; Markus Pirklbauer; Michael Rudnicki; Gert Mayer; Julia Kerschbaum Journal: J Clin Med Date: 2021-12-28 Impact factor: 4.241
Authors: Borja Quiroga; María José Soler; Alberto Ortiz; Carlos Jesús Jaravaca Mantecón; Nathasha Nava Pérez; Marta Serra Martín; Yurika Sato; Antonio José Marin Franco; Diana Flor Pazmiño Zambrano; Rafael Lucena Valverde; Mayra Ortega Diaz; Carmen Calderón González; Juan Manuel Cazorla López; Mónica Pereira; Emilio González Parra; Ana Sánchez Horrillo; Carmen Sánchez González; Néstor Toapanta; Secundino Cigarrán Guldris; Rosa Sánchez Hernández; Soledad Pizarro Sánchez; María Muñiz Rincón; Nuria Garcia-Fernández; Natalia Blanco Castro; Rocío Collantes Mateo; Manuel Augusto Quiroz Morales; Beatriz Escamilla-Cabrera; Isabel Berdud Godoy; Beatriz Gil-Casares Casanova; Alba Leyva; José Rojas; Ron T Gansevoort; Patricia de Sequera Journal: Clin Kidney J Date: 2022-07-26
Authors: Auxiliadora Mazuecos; Florentino Villanego; Sofía Zarraga; Verónica López; Federico Oppenheimer; Laura Llinàs-Mallol; Ana M Hernández; Alba Rivas; María C Ruiz-Fuentes; Néstor G Toapanta; Carlos Jiménez; Sheila Cabello; Isabel Beneyto; María J Aladrén; Alberto Rodríguez-Benot; Cristina Canal; María Molina; Isabel Pérez-Flores; Isabel M Saura; Eva Gavela; Antonio Franco; Inmaculada Lorenzo; Cristina Galeano; Guadalupe Tabernero; Lourdes Pérez-Tamajón; Paloma L Martín-Moreno; Fernando Fernández-Girón; Orlando Siverio; Pedro J Labrador; Gabriel De Arriba; Fernando Simal; Leónidas Cruzado; Inigo Moina; Guillermo Alcalde; Emilio Sánchez-Álvarez; Julio Pascual; Marta Crespo Journal: Transplantation Date: 2022-04-01 Impact factor: 5.385